卞金磊，药物化学博士，副教授，博士生导师。2011年本科毕业于中国药科大学制药工程专业，本科毕业后免推为中国药科大学制药工程专业硕博连读研究生，2016年获得中国药科大学理学博士学位，获得“江苏省优秀博士学位论文”称号。同年留校任教于药学院药物化学教研室。
作为课题负责人主持国家自然科学基金青年基金项目一项，江苏省自然科学基金青年基金一项，中央高校基本科研业务费项目一项。近五年来以第一作者和通讯作者在学科权威杂志Journal of Medicinal Chemistry, Green Chemistry, Organic Letter, The Journal of Organic Chemistry, European Journal of Medicinal Chemistry等发表论文35篇。
联系方式：bianjl@cpu.edu.cn
近年来主要研究课题方向：
1.肿瘤代谢谷氨酰胺酶（GLS1）化学生物学及小分子抑制剂的相关研究。
2.基于蛋白降解靶向嵌合体策略构建小分子调控剂用于恶性肿瘤的治疗。
3.靶向Wnt信号通路小分子调控剂的发现及在组织再生领域的研究。
4.近年来承担的主要科研项目：
课题来源
课题编号
课题名称
职责
进展情况

国家自然科学基金青年基金
**
基于细胞自组装蛋白水解靶向嵌合体策略设计新型CDK9小分子调控剂
负责人
在研

江苏省自然科学基金青年基金
BK**
基于蛋白降解靶向嵌合体策略构建CDK9 小分子调控剂的研究
负责人
在研

中国药科大学基本科研业务费
**PY13
基于蛋白降解新策略构建靶向CDK9小分子调控剂的研究
负责人
结题

近三年代表性论文及著作：
Yucheng Tian, Jubo Wang, Xinying Cheng, Kang Liu, Tizhi Wu, Xiaqiu Qiu, Zijian Kuang, Zhiyu Li* andJinlei Bian*. Green Chemistry, 2020, 22: 1338-1344. (IF = 9.48)
Tizhi Wu, Zhen Qin, Yucheng Tian, Jubo Wang, Chenxi Xu, Zhiyu Li* andJinlei Bian*. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. Journal of Medicinal Chemistry, 2019, 62: 9642?9657. (IF = 6.205)
Xi Feng, Dongyu Liu, Zhiyu Li* andJinlei Bian*. Bioactive modulators targeting STING adaptor in cGAS-STING pathway. Drug Discovery Today, 2020, 25: 230-237. (IF = 7.321)
Xi Xu, Zijian Kuang, Jie Han, Ying Meng, Lei Li, Hongyu Luan, Pengfei Xu, Jubo Wang, Cheng Luo, Hong Ding, Zhiyu Li,* and Jinlei Bian*. Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors. Journal of Medicinal Chemistry, 2019, 62: 9642?9657. (IF = 6.205)
Xi Xu, Ying Meng, Lei Li, Pengfei Xu, Jubo Wang, Zhiyu Li,* and Jinlei Bian*.Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions. Journal of Medicinal Chemistry, 2019, 62: 1096?1115. (IF = 6.205)
Pengfei Xu, Hongyu Luan, Bin Yu, Yongrui Tu, Yongqiang Sun, Wei Chen, Xi Xu, Raoling Ge, Jubo Wang, Zhiyu Li,* and Jinlei Bian*. Synthesis and characterization of potential stereoisomeric and degradation impurities of ulipristal acetate. Organic Chemistry Frontiers.2019, 6: 868-872. (IF = 5.155)
Xi Feng, Pei Shen, Yinuo Wang, Zhiyu Li^?,Jinlei Bian^?. Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO. Biochemical Pharmacology. 2019, 168: 214–223. (IF = 4.96)
Jubo Wang, Tinghan Li, Tengteng Zhao, Tizhi Wu, Chuang Liu, Hong Ding, Zhiyu Li*, Jinlei Bian*. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity. European Journal of Medicinal Chemistry. 2019, 178: 782-801. (IF = 5.572)
Qianming Du, Xi Feng, Yinuo Wang, Xi Xu, Yan Zhang, Xinliang Qu, Zhiyu Li, *, Jinlei Bian*. European Journal of Medicinal Chemistry.2019, 182: 111629. (IF = 5.572)
Jubo Wang, Tinghan Li, Tengteng Zhao, Tizhi Wu, Chuang Liu, Hong Ding, Zhiyu Li*, Jinlei Bian**. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.European Journal of Medicinal Chemistry. 2019, 178: 782-801. (IF = 5.572)
Tianwei Weng#, Xiaqiu Qiu, Jubo Wang, Zhiyu Li*, Jinlei Bian*. Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy. European Journal of Medicinal Chemistry, 2018, 143: 656-669. (IF =5.572)
Xi Xu#, Raoling Ge, Lei Li, Jubo Wang, Xiaoyu Lu, Siqi Xue, Xijing Chen, Zhiyu Li*, Jinlei Bian*. Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents. European Journal of Medicinal Chemistry, 2018, 143: 1325-1344. (IF = 5.572)
Xi Feng, Xiaqiu Qiu, Huidan Huang, Jubo Wang, Xi Xu, Pengfei Xu, Ruijia Ge, Xiaojin Liu, Zhiyu Li,* andJinlei Bian,*. Palladium(II)-Catalyzed Reaction of Lawsones and Propargyl Carbonates: Construction of 2,3-Furanonaphthoquinones and Evaluation as Potential Indoleamine 2,3-Dioxygenase Inhibitors. Journal of Organic Chemistry, 2018,83: 8003?8010. (IF = 5.572)